Category: Infused Products & Extracts

Creso Pharma Market Update

Highlight Creso completes due diligence for Mernova Medicinal Inc.’s Canadian medicinal cannabis growing facility Construction contract signed, ground works commenced in Canada and project is on track for completion in Q3 2018 Canada amends the Cannabis Act. Bill C-45 to allow edible cannabis products in 2019; opportunities for Creso’s cannaQIX® and cannapeal® product ranges Over 200,000 patients now registered for medicinal cannabis in Canada Nova Scotia opens public consultation on medicinal cannabis Mernova Medicinal and Creso join 16 other licenced producers and Ad Standards group to further self-regulation for the industry Creso Pharma Limited (ASX:CPH, the “Company” or “Creso”) is pleased to provide this market update: Due diligence completed for medicinal cannabis growing facility Creso has successfully completed due diligence on the Mernova Medicinal Inc. acquisition, a 20,000 square foot medical cannabis growing facility in Nova Scotia, Canada. Also, the application for a medical cannabis cultivation licence under Health Canada’s Access to Cannabis for Medical Purposes Regulation (ACMPR) program is progressing. It will give Creso a significant competitive advantage as one of the few companies globally and the only medicinal cannabis company listed on the ASX with 100% ownership and capacity to cultivate, extract and manufacture its own innovative cannabis and hemp derived human and animal therapeutic products in Canada. These products will be for local distribution as well as export to countries which accept cannabis and hemp imports....

Read More

Marapharm Ventures Inc. “Marapharm” announces a Private Placement of up to 80 million Share Purchase Warrants

SHARE THIS POST Marapharm announces the proposed offering of up to 80 million share purchase warrants. Each warrant will be offered for a consideration of 10 cents (CDN) per warrant for a total of gross proceeds of up to $8 million dollars and are exercisable into one common share for the price of $2.90 per share for a period of 3 years from the date of closing (the “warrants”). The proceeds will be utilized by Marapharm for development and corporate purposes. “This offering of warrants is unique. There is no immediate dilution and it provides up to $8 million...

Read More

Isodiol International Inc. receives regulatory (ANVISA) approval for Isoderm for the treatment of Epilepsy and Parkinson’s

SHARE THIS POST July 6, 2017 – Vancouver, Canada – Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce it has received approval from the Brazilian Health Regulatory Agency (ANVISA) for the approval of its pharmaceutical grade Cannabidiol (CBD) product, Isoderm™. This product will be placed on the Special Category List for alternative therapies which will enable it to be prescribed by doctors and neurologists. Isodiol International CEO Marcos Agramont stated, “We had initially anticipated this process to...

Read More

Cannabics Pharmaceuticals Receives Positive Results In Drug Sensitivity Tests On CTCs

SHARE THIS POST TEL AVIV, Israel, June 30, 2017 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) today announced it received positive results from screening necrosis (cell death) of circulating tumor cells, from cancer patients, treated with the cannabinoids CBD and CBDA. These results greatly strengthen the company’s previously accumulated data on cannabinoid anti-tumor activity. In addition, the screening results which indicate varied effectiveness of the tested cannabinoids upon different tumors (colon, breast, prostate) reaffirm the use of our proprietary technology in providing supportive data for personalized treatments. Dr. Eyal Ballan, CTO of Cannabics Pharmaceuticals noted “The screening of CTCs treated...

Read More

MYM and GGS Structures Working Together on Weeden Greenhouse Project

SHARE THIS POST Vancouver, B.C., June 29, 2017 – MYM Nutraceuticals Inc. (CSE:MYM) (OTC:MYMMF), is extremely pleased to announce that GGS Structures and CannaCanada Inc., subsidiary of MYM, are working together on the planning and design of the 1.5 Million sq. ft. Weedon Cannabis Greenhouse Production Project. Gerry Harrison of GGS Structures commented, “We are thrilled to be working with MYM Nutraceuticals on their project located at Weedon, Quebec. Planning is underway for the first phase of a greenhouse medical cannabis cultivation facility of approximately 100,000 sf. The completed state of the art growing facility will consist of 15...

Read More

Tinley Releases “Tinley Tonics” Hemp Extract Squeeze Supplement

SHARE THIS POST June 21, 2017: Santa Monica, California and Toronto, Ontario – The Tinley Beverage Company Inc. (the “Company” or “Tinley“) is pleased to announce the launch of its creamy chocolate squeeze supplement. The product contains 55 10mg servings of phytoconstituent-rich hemp extract, coconut-derived MCT oil, lactose-reduced whey protein, premium raw cacao as well as terpenes that are commonly found in whole-plant hemp extract. It is designed to be eaten on its own or mixed with coffee, smoothies, desserts and anything else that could be enjoyed with a chocolate twist. The squeeze supplement is also designed to be...

Read More
  • 1
  • 2